, ANZUP

Goal 4

ANNUAL

REPORT 2024

, ANZUP
, ANZUP

Goal 4

ANNUAL

REPORT 2024

, ANZUP

ANNUAL REPORT 2024

Goal 4

Goal 4: Forward plan to maintain a vibrant and active urogenital cancer trials

ANZUP actively fosters, collaborates, and expands its relationships with stakeholders through diverse avenues. Notably, the funding agreement with the Australian Government via Cancer Australia Support for Cancer Clinical Trials remains pivotal in supporting ANZUP’s infrastructure.

Donors, volunteers, philanthropists, corporate partners, and other key stakeholders remain a significant focus for ANZUP, particularly within the Partnerships and Engagement role. ANZUP continues to cultivate, oversee, and nurture these vital relationships.

Collaborative partnerships have been instrumental in enabling ANZUP to function at a high capacity. This is demonstrated by the four trials with other Cancer Cooperative Trials Groups (CCTGs) and our involvement in the Executive Officers Network (EON) and Clinical Trials Consumer Network (CTCN). The CTCN shares information amongst the groups’ Consumer Advisory Panels (CAPs) and EON reinforces links between groups by the sharing of concepts and resources.

In 2023/24, ANZUP collaborated with the NHMRC Clinical Trials Centre (CTC) at the University of Sydney on 15 clinical trials. Additionally, ANZUP partnered with the Centre for Biostatistics and Clinical Trials (BaCT) for 4 clinical trials, the Walter and Eliza Hall Institute of Medical Research (WEHI) for 1 trial, the Hunter Medical Research Institute (HMRI) for 1 trial, and The George Institute for Global Health (TGI) for 2 trials. These established affiliations guarantee vigorous processes on trial development and operations. 

Furthermore, ANZUP extends its collaborative efforts through co-badged trials, featuring 1 trial each with TROG, A/Prof Ben Tran, and Peter MacCallum Cancer Centre. 

Key Relationships

  • Australia & New Zealand Urological Nurses Society (ANZUNS) – represented on the ANZUP SAC by Kath Schubach
  • Australian Clinical Trials Alliance (ACTA)
  • Cancer Australia
  • Cancer Councils
  • Clinical Oncology Society of Australia (COSA)
  • Colleges (e.g. RACP, RANZCR, RACS)
  • Medical Oncology Group of Australia
  • Movember
  • Prostate Cancer Foundation Australia (PCFA)
  • TROG (Trans Tasman Radiation Oncology Group) Cancer Research
  • Other National Cancer Cooperative Trials Groups
  • Urological Society of Australia & New Zealand (USANZ)
  • Walter and Eliza Hall Institute of Medical Research (WEHI)

International Partnerships and Collaborations

  • Alliance for Clinical Trials in Oncology
  • Canadian Cancer Trials Group (CCTG)
  • Cancer Research UK
  • Cancer Trials Ireland (CTI)
  • Children’s Oncology Group (COG)
  • Dana-Farber Cancer Institute
  • European Organisation for Research and Treatment of Cancer (EORTC)
  • Medical Research Council (MRC) UK
  • National Cancer Institute
  • Prostate Cancer Clinical Trials Consortium (PCCTC)
  • Prostate Cancer Foundation New Zealand (PCFNZ)

ANZUP’s multidisciplinary membership remains the most valuable stakeholder relationship.  For members, ANZUP provides an annual calendar filled with educational and networking opportunities. In the 2023/24 period, this encompassed Ideas Generation Workshops, the Annual Scientific Meeting, the GU Cancer Rapid Fire Program, educational workshops and events, as well as grant opportunities, scholarships, fellowships, and awards. These initiatives serve to consistently support fellows, trainees, and junior researchers. By linking them with experts in their respective fields, these events facilitate skill development, knowledge enhancement, critical evaluation of research areas, and active involvement in the trial development process. Furthermore, our collaboration with PCFA to improve access to, and funding for, prostate cancer trials has strengthened another crucial relationship.

Regular email, print, and social media updates are routinely distributed and shared with the ANZUP membership. Being an ANZUP member affords individuals the opportunity to stay abreast of the latest developments in GU clinical trials research, networking opportunities, and the possibility to participate in educational sessions.